eMed is the world's first end-to-end GLP-1 care platform built on Empathetic AI™ — combining at-home diagnostics, physician-directed prescribing, and continuous adherence coaching to help healthcare employers reduce obesity-related cost exposure and improve long-term population health outcomes.
The Challenge
Healthcare employers are facing a growing and costly obesity crisis that is directly driving up medical claims, pharmacy spend, and long-term catastrophic risk exposure — with no structured clinical management framework in place to address it.
Employee demand for GLP-1 medications is accelerating, but most employers lack a supervised prescribing and adherence framework — resulting in fragmented access, inconsistent outcomes, and unmanaged spend.
Growing prevalence of Type 2 diabetes, cardiovascular disease, and other obesity-driven conditions is increasing catastrophic claim frequency and long-term cost trajectory.
Without structured clinical support, GLP-1 medication adherence rates are low — meaning employers absorb significant pharmacy spend while capturing minimal clinical benefit.
Most GLP-1 programs offer no real-time reporting on participation, adherence, or health outcomes — leaving HR and finance leaders without data to evaluate program performance or ROI.
Unmanaged obesity-related chronic disease is a primary driver of catastrophic claims and stop loss premium increases — creating compounding cost exposure year over year.
As GLP-1 benefits become an expectation rather than a differentiator, employers without a structured program face recruitment and retention disadvantages in competitive labor markets.
The eMed AP3 Solution
eMed delivers a fully integrated, clinically supervised GLP-1 management program — from eligibility screening through long-term adherence support — designed to improve outcomes and protect employer health plan economics.
eMed's GLP-1/GIP Program Screening Kit™ enables convenient, proctor-guided at-home biometric screening and lab testing with clinical review for eligibility determination — removing access barriers from day one.
Licensed clinician oversight ensures appropriate GLP-1 prescribing, ongoing medication management, and clinical accountability throughout the program — not just at intake.
Weekly clinical check-ins and around-the-clock adherence coaching and side-effect support drive meaningful improvements in medication adherence and long-term outcomes.
Partnership with programs like Thrive Global embeds behavioral health and lifestyle support alongside clinical management — addressing the whole person, not just the prescription.
De-identified, real-time reporting on program participation, adherence rates, and population health outcomes gives HR and finance leaders the visibility needed to evaluate program performance and manage plan economics.
Seamless integration with pharmacy benefit managers and employer HR and benefits platforms ensures coordinated program delivery without disrupting existing workflows.
eMed has served more than 6 million global customers since 2020 — with strategic investment from Aon validating its enterprise-grade population health impact.
Is This Right for Your Organization?
The eMed AP3 solution is purpose-built for self-funded healthcare employers experiencing rising GLP-1 demand, obesity-related claim volatility, and the need for a clinically credible, outcomes-driven benefit solution.
GLP-1 prescriptions are increasing across the covered population without a structured clinical management framework in place.
Chronic conditions tied to obesity — including Type 2 diabetes and cardiovascular disease — are driving claims frequency and stop loss exposure.
Employees are accessing GLP-1 medications through fragmented or unsupervised channels, creating clinical and financial risk.
Current benefit programs offer no employer-facing data on participation, adherence, or clinical outcomes.
Catastrophic claim exposure linked to obesity-related comorbidities is driving renewal volatility and underwriting scrutiny.
A clinically supervised GLP-1 program supports recruitment and retention by demonstrating meaningful investment in workforce health.
Why Through AP3
As a vetted Strategic Partner within the ASHHRA Preferred Partner Program, eMed's engagement is structured to deliver more than a standard vendor relationship.
eMed's capabilities and healthcare alignment have been formally evaluated through AP3's structured governance process.
Engagements are coordinated through AP3 to ensure strategic alignment and executive-level transparency from the outset.
Special pricing considerations and partner incentives are available exclusively through AP3 — not through direct outreach.
eMed's GLP-1 program connects directly to AP3's stop loss strategy through Lockton — creating a coordinated approach to reducing catastrophic claim exposure at both the clinical and financial level.
Request a Structured Evaluation
Complete the form and an AP3 representative will connect you with eMed to discuss your GLP-1 management and population health challenges. Engagements are coordinated through AP3 to ensure alignment and access to pre-negotiated terms.
Your information is secure. We'll respond within 1–2 business days.